

CORRESPONDENCE

Open Access



Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”

Fereshteh Behdarvand Dehkordi^{1,2} and Mohammad Chehelgerdi^{1,2*}

Dear Editor,

I am writing to provide a comparative analysis of the recently published study titled “Cerebrospinal fluid CAMK2A levels at baseline predict long-term progression in multiple sclerosis” conducted by Sohaei et al. [1]. (Clinical Proteomics. 2023 Dec;20(1):1–2). Given the significant findings of this study, it is crucial to assess its contributions in relation to existing research to offer a comprehensive perspective on the subject matter.

To conduct a comparative analysis of the study titled “Cerebrospinal fluid CAMK2A levels at baseline predict long-term progression in multiple sclerosis” with other references, we would need to gather related studies that investigate CSF biomarkers in multiple sclerosis. Some points to consider for the comparative analysis could include:

Firstly, future work based on this study should look at expanding the sample size so that results are more generalizable across the MS patient population. This can potentially provide valuable insight into treatment modalities and outcomes. Additionally, the research could expand to consider the interaction of these biomarkers with other predictive or risk factors for MS. This comprehensive approach may contribute to the

development of a more robust prognostic tool. Furthermore, a rigorous validation of these biomarkers should be performed in larger cohorts and various stages of disease progression. Moreover, validation of current findings might also reveal whether the predictive power of these biomarkers changes over the course of the disease [2].

In addition, while CAMK2A is a promising biomarker for future exploration, the functional role of this protein in MS pathophysiology should be analyzed in the context of other potential interacting proteins or pathways that could influence disease severity. Lastly, the cost and feasibility of using such an analytical methodology, like targeted liquid-chromatography tandem mass spectrometry, in a clinical setting is another aspect to be considered in future studies. The translation of these findings into actual clinical application may also face significant technological or procedural barriers that will need to be addressed [3].

Given these findings, future work could involve validation of novel CSF biomarkers with a focus on CAMK2A, in additional large-scale, independent cohorts of MS patients, as the published results were obtained from a relatively limited sample size. Further examination could also review these biomarkers’ predictive value in secondary progressive MS, as well as their association with different disease-modifying treatments. Moreover, a longitudinal study design could offer a deeper understanding of their role and variability over time and alongside disease progression. Applying other highly sensitive and specific analytical techniques could also unearth more

*Correspondence:

Mohammad Chehelgerdi
Chehelgerdi1992@gmail.com

¹Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran

²Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

novel biomarkers, and the integration of these proteomic data with other “omics” data warrants investigation [3, 4].

Authors' contributions

FB. and M.C. wrote the main manuscript text. All authors reviewed and approved the final manuscript.

Funding

No funding.

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

No application.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 2 September 2023 / Accepted: 4 October 2023

Published online: 25 October 2023

References

1. Sohaei D, Thebault S, Avery LM, Batruch I, Lam B, Xu W, Saadeh RS, Scarisbrick IA, Diamandis EP, Prassas I, Freedman MS. Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. *Clin Proteomics*. 2023;20(1):1–2.
2. Chertcoff A, Ng HS, Zhu F, Zhao Y, Tremlett H. Polypharmacy and multiple sclerosis: a population-based study. *Multiple Scler J*. 2023;29(1):107–18.
3. Schirò G, Iacono S, Ragonese P, Aridon P, Salemi G, Balistreri CR. A brief overview on BDNF-Trk pathway in the nervous system: a potential biomarker or possible target in treatment of multiple sclerosis. *Front Neurol*. 2022;13:917527.
4. Rayaprolu S, Bitarafan S, Santiago JV, Betarbet R, Sunna S, Cheng L, Xiao H, Nelson RS, Kumar P, Bagchi P, Duong DM. Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain. *Nat Commun*. 2022;13(1):2927.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.